#1 Clinical Trials Search in Europe

OXYBUTYNIN HYDROCHLORIDE

Oxybutynin hydrochloride is a medication that has been extensively studied in clinical trials for various conditions. It belongs to a class of drugs called anticholinergics, which work by blocking certain nerve signals in the body. This article examines how oxybutynin hydrochloride has been used in clinical trials, focusing on its effectiveness, different administration methods, and potential side effects. Research shows that this medication has applications beyond its traditional use for overactive bladder, including treatment for hyperhidrosis (excessive sweating), hot flashes, and as part of combination therapy for sleep apnea and other conditions.

# Oxybutynin Hydrochloride: A Comprehensive Guide for Patients Table of Contents – [What is Oxybutynin Hydrochloride?](#what-is-oxybutynin-hydrochloride) – [How Does Oxybutynin Hydrochloride Work?](#how-does-oxybutynin-hydrochloride-work) – [Medical Uses](#medical-uses) – [Available Formulations](#available-formulations) – [Dosage Information](#dosage-information) – [Effectiveness](#effectiveness) – [Side Effects](#side-effects) – [Special Patient Populations](#special-patient-populations) – [Drug Interactions](#drug-interactions) – [New and Emerging Uses](#new-and-emerging-uses) What is Oxybutynin Hydrochloride? Oxybutynin hydrochloride is a medication that belongs to the class of drugs known as anticholinergics or antimuscarinic agents. It was first developed to treat conditions related to bladder overactivity and has been in clinical use for several decades. The drug is also known by several brand names including Ditropan, Ditropan XL, Oxytrol, Gelnique, and others depending on the country and formulation [1]. How Does Oxybutynin Hydrochloride Work? Oxybutynin works by blocking specific receptors called muscarinic receptors, particularly in the bladder muscle (detrusor). This action: – Relaxes the detrusor muscle in the bladder – Decreases bladder contractions and spasms – Increases bladder capacity – Reduces the urgency to urinate – Improves continence By affecting these muscarinic receptors, oxybutynin effectively reduces involuntary bladder contractions that can cause symptoms such as urgency, frequency, and urinary incontinence [2]. Medical Uses # Overactive Bladder (OAB) Oxybutynin hydrochloride is primarily used to treat overactive bladder syndrome, which includes symptoms such as: – Urinary urgency (sudden, compelling need to urinate) – Frequency (urinating more often than normal) – Urge incontinence (involuntary urine leakage associated with urgency) – Nocturia (waking up at night to urinate) Clinical trials have shown that oxybutynin reduces these symptoms in adults with OAB, improving quality of life and reducing the number of incontinence episodes [3]. # Neurogenic Bladder Oxybutynin is effective in treating neurogenic bladder, a condition where nerve damage affects bladder function. This is common in patients with: – Spina bifida – Multiple sclerosis – Spinal cord injuries – Other neurological conditions In children with neurogenic bladder due to spina bifida, intravesical oxybutynin (administered directly into the bladder) has shown promising results in improving bladder capacity and reducing intravesical pressure, which can help protect kidney function over time [4]. # Nocturnal Enuresis (Bedwetting) Oxybutynin may also be prescribed for nocturnal enuresis in children, though it’s typically not a first-line treatment. Studies have compared it with other medications like desmopressin (Minirin) for this condition [5]. # Hyperhidrosis (Excessive Sweating) An off-label use of oxybutynin is for the treatment of hyperhidrosis, or excessive sweating. Clinical trials have demonstrated that oxybutynin can reduce sweating in various areas of the body, including: – Palmar (hands) – Plantar (feet) – Axillary (underarms) – Craniofacial (face and head) Patients with hyperhidrosis often experience significant improvement in their quality of life when treated with oxybutynin [6]. # Hot Flashes Oxybutynin has shown promise in treating hot flashes in women undergoing endocrine therapy after breast cancer, as well as in women who are not candidates for hormone replacement therapy. This represents another important off-label use of the medication [7]. Available Formulations Oxybutynin hydrochloride is available in several formulations, each with different characteristics: # Oral Immediate-Release (IR) – Tablets or syrup – Usually taken 2-3 times daily – Faster onset but shorter duration of action – More prone to cause side effects due to peaks in blood concentration # Oral Extended-Release (XL/ER) – Once-daily dosing (e.g., Ditropan XL) – More steady blood levels throughout the day – May have fewer side effects than immediate-release form – Easier compliance due to once-daily dosing – Available as OROS (Oral Osmotic System) delivery system # Transdermal Patch – Applied to the skin (e.g., Oxytrol) – Delivers medication continuously through the skin – Changed twice weekly (every 3-4 days) – Bypasses first-pass metabolism in the liver, potentially reducing certain side effects # Topical Gel – Applied to the skin (e.g., Gelnique 3% or 10%) – Once-daily application – Less dry mouth compared to oral formulations – May cause skin irritation at application site # Intravesical – Administered directly into the bladder via catheter – Used primarily for neurogenic bladder – May provide local effects with fewer systemic side effects – Less commonly used in routine practice [8] Dosage Information Dosing of oxybutynin varies based on the formulation, patient age, condition being treated, and individual response. General guidelines include: # Adults with Overactive Bladder: – Immediate-release tablets: 5 mg 2-3 times daily (maximum 5 mg 4 times daily) – Extended-release tablets: 5-10 mg once daily, can be increased to 30 mg once daily – Transdermal patch: 3.9 mg/day patch applied twice weekly – Topical gel: 1 gram (containing 100 mg oxybutynin) applied once daily # Children with Neurogenic Bladder: – Typically started at lower doses based on weight (approximately 0.2-0.4 mg/kg/day) – For intravesical use in children: 0.4 mg/kg/day in 2-3 instillations – Maximum dose varies by age: – Ages 6-11 years: up to 20 mg/day – Ages 12-17 years: up to 30 mg/day # For Hyperhidrosis (Off-label): – Often started at a low dose (2.5 mg once daily) – Gradually increased to 2.5 mg twice daily, then potentially to 5 mg twice daily – Topical formulations (10% gel) may also be used for focal hyperhidrosis [9] Effectiveness # Overactive Bladder Clinical trials have consistently shown that oxybutynin effectively reduces symptoms of overactive bladder. Key findings include: – Reduction in urinary incontinence episodes by 50% or more in many patients – Increased bladder capacity – Decreased urinary frequency – Improved quality of life measures – Beneficial effects typically seen within 1-2 weeks of starting treatment Studies comparing different formulations have found that extended-release versions maintain efficacy while potentially reducing side effects [10]. # Neurogenic Bladder In patients with neurogenic bladder, particularly children with spina bifida, oxybutynin has demonstrated: – Increased maximum bladder capacity – Decreased maximum bladder pressure – Reduced risk of upper urinary tract damage – Improved continence between catheterizations Intravesical administration may be particularly effective in patients who have inadequate response to oral anticholinergics or experience intolerable side effects [11]. # Hyperhidrosis For hyperhidrosis, clinical trials have reported: – Significant reduction in sweating in various body areas – Improvement in Hyperhidrosis Disease Severity Scale (HDSS) scores – Enhanced quality of life – Effects typically noticeable within 1-2 weeks – Sustained benefits with continued treatment Many patients report being “satisfied” or “highly satisfied” with oxybutynin treatment for hyperhidrosis [12]. Side Effects As with any medication, oxybutynin hydrochloride can cause side effects. These vary in frequency and severity based on the formulation used and individual factors. # Common Side Effects – **Dry mouth** (most common, affecting up to 70% of patients on oral formulations) – **Constipation** – **Blurred vision** – **Dry eyes** – **Drowsiness or dizziness** – **Headache** – **Urinary retention** (difficulty emptying the bladder completely) # Less Common Side Effects – **Confusion** (more common in elderly patients) – **Gastrointestinal disturbances** (nausea, abdominal pain) – **Increased heart rate** – **Flushing** – **Skin reactions** (with transdermal or topical formulations) – **Decreased sweating** (may lead to overheating in hot environments) # Formulation-Specific Side Effects – **Transdermal patch**: Skin irritation, redness, or itching at application site – **Topical gel**: Application site reactions – **Intravesical administration**: Local irritation, pain during instillation The extended-release oral formulations and transdermal/topical formulations generally have fewer systemic side effects, particularly dry mouth, compared to immediate-release oral formulations. This is because they avoid the high peak blood levels associated with immediate-release tablets and may reduce metabolism to the active metabolite (N-desethyloxybutynin) responsible for many side effects [13]. Special Patient Populations # Children Oxybutynin is one of the few anticholinergic medications approved for use in children with neurogenic bladder. Important considerations include: – Dosing is typically weight-based – Children may be more sensitive to certain side effects, particularly CNS effects – Transdermal formulations may be beneficial for children who have difficulty swallowing tablets – Regular monitoring of response and side effects is essential – Long-term safety has been established through clinical experience # Elderly Patients Older adults may be more susceptible to certain side effects of oxybutynin, particularly: – Confusion and cognitive effects – Dry mouth and constipation – Urinary retention Lower starting doses and careful monitoring are recommended. Extended-release formulations or transdermal delivery systems may be preferable in this population to minimize side effects [14]. # Patients with Neurological Conditions For patients with spina bifida or other neurological conditions affecting the bladder: – Oxybutynin is often used in conjunction with clean intermittent catheterization – Regular urodynamic testing may be needed to assess effectiveness – Alternative administration routes (intravesical) may be considered in case of inadequate response or intolerable side effects – The medication helps prevent kidney damage by reducing bladder pressure Drug Interactions Oxybutynin may interact with other medications, including: – **Other anticholinergic drugs**: Combining with other anticholinergics can increase side effects – **Alcohol**: May enhance drowsiness or dizziness – **Certain antifungals and antibiotics**: May increase oxybutynin blood levels – **Medications that affect liver enzymes**: May alter oxybutynin metabolism Patients should always inform their healthcare providers about all medications, supplements, and herbal products they are taking [15]. New and Emerging Uses Research continues to explore new applications for oxybutynin: # Sleep Apnea Treatment Recent studies have investigated the combination of oxybutynin with atomoxetine for treating obstructive sleep apnea, showing promising results in reducing apnea-hypopnea index in certain patient subgroups [16]. # Post-surgical Pain Management Oxybutynin is being evaluated for managing bladder pain and urinary urgency after surgical procedures, with some evidence suggesting benefit for reducing stent-related discomfort following urological procedures [17]. # Combination Therapies Research is exploring combination therapies, such as oxybutynin with alpha-blockers (tamsulosin) for treating lower urinary tract symptoms, which may provide superior symptom relief compared to monotherapy [18].
Aspect Details
Primary Indications – Overactive bladder (neurogenic and non-neurogenic)
– Urinary incontinence
– Detrusor overactivity
– Neurogenic bladder in children with spina bifida
Emerging Applications – Hyperhidrosis (excessive sweating)
– Hot flashes in women with breast cancer or on endocrine therapy
– Component in combination therapy for obstructive sleep apnea
– Post-surgical bladder pain and discomfort
– Management of ureteral stent discomfort
– Nocturnal enuresis in children
Administration Routes – Oral tablets (immediate-release and extended-release)
– Transdermal patches
– Topical gels (3% and 10% formulations)
– Intravesical instillation (directly into bladder)
Dosage Ranges – Oral: 2.5mg to 30mg daily (varies by age and indication)
– Transdermal: 3.9mg/day patches
– Topical gel: 56mg to 84mg daily
– Intravesical: 0.4mg/kg/day in 2-3 instillations
Common Side Effects – Dry mouth (xerostomia)
– Constipation
– Blurred vision
– Drowsiness
– Skin reactions (with transdermal applications)
Benefits of Alternate Routes – Transdermal/intravesical routes bypass first-pass metabolism
– Reduced production of desethyloxybutynin (metabolite responsible for side effects)
– Lower incidence of systemic side effects
– Potentially higher patient compliance
Special Population Considerations – Pediatric dosing based on weight
– Alternative delivery methods for children who cannot swallow pills
– Careful monitoring in children for developmental effects
– Contraindications include glaucoma, myasthenia gravis
Comparison Studies – Versus placebo (multiple studies)
– Versus oral oxybutynin (transdermal and intravesical routes)
– Versus other anticholinergics (solifenacin, trospium)
– In combination with other medications (tamsulosin, atomoxetine)
Outcome Measures – Bladder capacity
– Urinary incontinence episodes
– Catheterization volumes
– Quality of life measurements
– Patient-reported symptom improvement
– Urodynamic parameters (pressure, compliance)

FAQ

  • What conditions is oxybutynin hydrochloride used to treat in clinical trials? Oxybutynin hydrochloride has been studied in clinical trials for multiple conditions, including overactive bladder (both neurogenic and non-neurogenic), urinary incontinence, hyperhidrosis (excessive sweating), hot flashes in women with breast cancer or on endocrine therapy, and as part of combination therapy for obstructive sleep apnea. It's also been investigated for post-surgical bladder pain and urgency, management of ureteral stent discomfort, and nocturnal enuresis (bedwetting) in children.
  • How is oxybutynin hydrochloride administered in clinical trials? Clinical trials have explored multiple routes of administration for oxybutynin hydrochloride, including oral tablets (immediate-release and extended-release formulations), transdermal patches, topical gels, and intravesical (directly into the bladder) instillation. Each method has different benefits – for example, transdermal and intravesical routes often produce fewer systemic side effects than oral administration because they bypass first-pass metabolism in the liver, which creates metabolites responsible for many side effects.
  • What are the common side effects observed in oxybutynin hydrochloride clinical trials? Common side effects observed in clinical trials include dry mouth, constipation, blurred vision, drowsiness, dizziness, and headache. For transdermal applications, skin irritation at the application site may occur. The severity and frequency of side effects often depend on the dose and route of administration. Transdermal and intravesical routes typically produce fewer systemic side effects compared to oral administration. In children, particular attention is paid to monitoring for adverse effects that might interfere with brain development.
  • Is oxybutynin hydrochloride effective for treating neurogenic bladder in children? Clinical trials have investigated oxybutynin hydrochloride for treating neurogenic bladder in children, particularly those with spina bifida. Studies have shown it can be effective in improving bladder capacity, reducing intravesical pressure, and decreasing incontinence episodes. Various administration routes have been studied, including oral, transdermal, and intravesical methods. One trial specifically compared intravesical oxybutynin to placebo in children with overactive neurogenic bladder who had inadequate response to oral anticholinergics, looking to extend the time before more invasive procedures became necessary.
  • Are there new or emerging uses for oxybutynin hydrochloride being explored? Yes, clinical trials are exploring several new uses for oxybutynin hydrochloride beyond its traditional application for bladder conditions. These include treatment for hyperhidrosis (excessive sweating), management of hot flashes in women undergoing endocrine therapy after breast cancer, combination therapy with atomoxetine for obstructive sleep apnea, and use in post-surgical pain management. The medication is also being studied in various formulations (topical, transdermal) to reduce systemic side effects while maintaining effectiveness for both traditional and new indications.

Ongoing Clinical Trials on OXYBUTYNIN HYDROCHLORIDE

  • Study on the Effectiveness of Oxybutynin for Children with Overactive Neurogenic Bladder Due to Spina Bifida

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France

Glossary

  • Anticholinergic: A class of medications that block the action of acetylcholine, a neurotransmitter, at synapses in the central and peripheral nervous system. Oxybutynin is an anticholinergic that specifically targets receptors in the bladder muscle, helping to reduce muscle spasms and urgency.
  • Bioavailability: The proportion of a drug that enters circulation when introduced into the body and so is able to have an active effect. Transdermal oxybutynin has higher bioavailability than oral forms because it bypasses initial metabolism in the liver.
  • Cystomanometry: A urodynamic test that measures pressure and volume relationships in the bladder, used to assess bladder function. In clinical trials for neurogenic bladder, this test helps measure maximum bladder capacity and pressure.
  • Detrusor Overactivity: A urodynamic observation characterized by involuntary detrusor (bladder muscle) contractions during the filling phase of cystometry. It's a key feature of overactive bladder that oxybutynin aims to control.
  • Desethyloxybutynin (DEO): The primary metabolite of oxybutynin produced by liver metabolism. It is responsible for many of the side effects associated with oral oxybutynin administration, particularly dry mouth and constipation.
  • First-pass metabolism: The process by which a drug's concentration is greatly reduced before it reaches systemic circulation, typically by the liver. Oral oxybutynin undergoes significant first-pass metabolism, producing desethyloxybutynin which causes many side effects.
  • Hyperhidrosis: A condition characterized by excessive sweating beyond what's necessary for normal temperature regulation. Several clinical trials have explored oxybutynin as a treatment for primary focal hyperhidrosis affecting the palms, soles, axillae (armpits), or face.
  • Intravesical: Referring to administration of a substance directly into the bladder, typically through a catheter. Intravesical oxybutynin is being studied for treating neurogenic bladder in children to potentially avoid systemic side effects.
  • Neurogenic Bladder: Bladder dysfunction caused by a neurological condition affecting the brain, spinal cord, or nerves. In children with spina bifida, it often leads to small bladder capacity, poor compliance, and overactivity, which can be treated with oxybutynin.
  • OROS (Oral Osmotic System): A controlled drug delivery technology used in some extended-release formulations of oxybutynin. It provides continuous delivery of medication over a prolonged period, allowing for once-daily dosing.
  • Overactive Bladder (OAB): A condition characterized by urinary urgency, often accompanied by frequency and nocturia, with or without urge urinary incontinence. It's the primary condition for which oxybutynin was originally developed and approved.
  • Spina Bifida: A birth defect where the spinal column doesn't form properly, often affecting bladder innervation and leading to neurogenic bladder. Children with spina bifida frequently require treatment with medications like oxybutynin to manage bladder function.
  • Transdermal: A route of drug administration where the drug is absorbed through the skin. Transdermal oxybutynin (patches or gels) bypasses first-pass metabolism in the liver, potentially reducing certain side effects compared to oral administration.
  • Urinary Incontinence: The involuntary leakage of urine. Urge incontinence, often associated with overactive bladder, is a type that can be treated with oxybutynin by reducing the urgency and frequency of urination.
  • Urodynamic Studies: Diagnostic tests that assess how well the bladder, sphincters, and urethra store and release urine. These tests are used in clinical trials to objectively measure the effects of oxybutynin on bladder function.

References

  1. https://clinicaltrials.gov/study/NCT03952299
  2. https://clinicaltrials.gov/study/NCT00749632
  3. https://clinicaltrials.gov/study/NCT00613327
  4. https://clinicaltrials.gov/study/NCT07027020
  5. https://clinicaltrials.gov/study/NCT02538302
  6. https://clinicaltrials.gov/study/NCT01956591
  7. https://clinicaltrials.eu/trial/study-on-oxybutynin-and-venlafaxine-for-reducing-hot-flashes-in-women-undergoing-endocrine-therapy-after-breast-cancer/
  8. https://clinicaltrials.gov/study/NCT03205605
  9. https://clinicaltrials.gov/study/NCT01855256
  10. https://clinicaltrials.gov/study/NCT00909181
  11. https://clinicaltrials.gov/study/NCT00224016
  12. https://clinicaltrials.gov/study/NCT01118429
  13. https://clinicaltrials.gov/study/NCT00304499
  14. https://clinicaltrials.gov/study/NCT07081906
  15. https://clinicaltrials.gov/study/NCT00269724
  16. https://clinicaltrials.gov/study/NCT05550246
  17. https://clinicaltrials.gov/study/NCT05100017
  18. https://clinicaltrials.gov/study/NCT00338624